CA-ESRI
6.10.2020 14:02:19 CEST | Business Wire | Press release
Esri , the global leader in location intelligence, today announced two major capabilities in Site Scan for ArcGIS that will enable governments and critical infrastructure organizations to meet hardware and software regulations in the US and Europe. Through an established partnership with Auterion, creator of the most widely used open-source drone autopilot operating system, security-conscious US organizations will be able to use Site Scan, Esri's unmanned aerial systems flight planning and processing solution, to plan and execute missions with the trusted and secure Freefly Astro drone, powered by Auterion. Additionally, for organizations in Europe with data sovereignty requirements, a new and fully independent instance of Site Scan for ArcGIS has been deployed to European servers, ensuring that organizational data resides within the region.
Site Scan for ArcGIS is used by organizations that require drone imagery for visual inspections, site monitoring, asset management, and situational awareness. It's an all-in-one, cloud-based drone mapping solution for managing fleets and collecting, processing, analyzing, and sharing data products. Industries using this solution include architecture, engineering, construction, natural resources, infrastructure, and government. Core capabilities in Site Scan—such as scalability, collaboration, time saving, and now enhanced security functionality—provide value to customers.
The US government has recently issued a growing number of advisory warnings and bans on the use of drones that pose security risks. These precautions have adversely impacted federal agencies and private firms that manage critical infrastructure, causing them to adopt incongruous drone data capturing and processing workflows that consist of multiple vendor solutions. Esri can now offer these agencies a single, end-to-end drone solution that integrates Freefly Astro, using US Department of Defense-approved Blue sUAS software architecture from Auterion, and is fully supported by Site Scan.
"Our expertise in providing an enterprise drone platform based on open-source software enabled us to meet the needs of the US government and governments worldwide," said Dave Sharpin, CEO, Auterion Government Solutions. "We are very excited to partner with Esri and provide [its] users with our groundbreaking technology."
By law within Europe, data from publicly funded or critical infrastructure projects cannot leave the European Union (EU). To enable a scalable drone workflow, Site Scan for ArcGIS has been deployed to a server cluster in Ireland. European customers that require their data not be transmitted outside the region can now leverage this server cluster to meet project requirements.
"The relationship we have established with Auterion is key in being able to offer high-quality, secure drone software to our US customers looking to take advantage of our advanced, secure, drone-based imagery collection and management platform," said Richard Cooke, Esri director of imagery and remote sensing. "Additionally, through the development of the EU deployment, an even wider range of customers located in Europe will be able to maintain their data and data processing locally."
The Freefly Astro and Site Scan integration will be available for customers by December 2020. The European deployment of Site Scan is available today. To learn more about the new integration of Site Scan with the Freefly Astro drone or about the EU deployment of Site Scan, contact the Esri sales team at esri.com/en-us/arcgis/products/site-scan-for-arcgis/overview#contactsales .
About Auterion
Auterion provides enterprise and government with an ecosystem of software-defined drones, payloads, and third-party applications within a single easy to use platform based on open-source standards.
With 50+ employees across offices in California and Switzerland, Auterion has raised $25M in venture-backed funding from investors such as Lakestar, Mosaic Ventures, Costanoa Ventures, and Tectonic Ventures. The company's global customer base includes GE Aviation, Quantum Systems, Freefly Systems, Avy, and the U.S. Government. Learn more at www.auterion.com .
Twitter: @auterion
LinkedIn: https://www.linkedin.com/company/auterion/
Facebook: https://www.facebook.com/auterion/
About Esri
Esri, the global market leader in geographic information system (GIS) software, location intelligence, and mapping helps customers unlock the full potential of data to improve operational and business results. Founded in 1969, Esri software is deployed in more than 350,000 organizations including 90 of the Fortune 100 companies, all 50 state governments, more than half of all counties (large and small), and 87 of the Forbes Top 100 Colleges in the U.S., as well as all 15 Executive Departments of the U.S. Government and dozens of independent agencies. With its pioneering commitment to geospatial information technology, Esri engineers the most advanced solutions for digital transformation, the Internet of Things (IoT), and advanced analytics. Visit us at esri.com .
Copyright © 2020 Esri. All rights reserved. Esri, the Esri globe logo, ArcGIS, The Science of Where, esri.com, and @esri.com are trademarks, service marks, or registered marks of Esri in the United States, the European Community, or certain other jurisdictions. Other companies and products or services mentioned herein may be trademarks, service marks, or registered marks of their respective mark owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201006005312/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom